In this issue
As the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve, ARASEC used an innovative study design to address a setting where an androgen deprivation therapy (ADT)-only control arm was no longer feasible. This AMJ article summarizes key data from the Phase II ARASEC study and explores how its protocol-specified external control arm may help inform future prostate cancer trials.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles
We’ve noticed you’re accessing
from North/South America.
from North/South America.